EUCTR2004-001043-30-IT进行中（未招募）不适用
A non-comparative, randomized phase II study of two different oral schedules of gimatecan (ST1481) as second line therapy for patients with advanced Non Small Cell Lung Cancer (NSCLC)
SIGMA-TA0 个研究点开始时间: 2005年3月7日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
1 期
A non-comparative randomized phase II study evaluating atezolizumab in combination with docetaxel, cisplatin, and 5-fluorouracil for the treatment of metastatic or unresectable locally advanced squamous cell anal carcinomaMetastatic or unresectable locally advanced squamous anal carcinomaMedDRA version: 20.0Level: LLTClassification code 10002141Term: Anal carcinomaSystem Organ Class: 100000004864EUCTR2017-003185-27-FRGERCOR99
招募中
2 期
“A phase II randomized non-comparative study, with NEOadjuvant plus adjuvant Therapy with combination or sequence of vemurafenib, cobImetinib, and atezolizuMab in patients with high-risk, surgically resectable BRAF mutated and wild-type Melanoma”2024-516659-41-00Fondazione Melanoma Onlus94
进行中（未招募）
1 期
A randomized, non-comparative, phase II study investigating the best epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) sequence in advanced or metastatic non-small-cell lung cancer (NSCLC) harboring EGFR mutationsAdvanced or metastatic untreated EGFR mutation positive NSCLCMedDRA version: 21.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2019-002869-35-ITFONDAZIONE RICERCA TRASLAZIONALE (FORT)189
进行中（未招募）
1 期
A randomized, non-comparative, phase II study investigating the best epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) sequence in advanced or metastatic non-small-cell lung cancer (NSCLC) harboring EGFR mutationsEUCTR2019-002869-35-ESFONDAZIONE RICERCA TRASLAZIONALE (FORT)189
终止
2 期
A Study Of PF-04691502 And PF-05212384 In Patients With Recurrent Endometrial CancerEndometrial NeoplasmsJPRN-jRCT2080221700Pfizer Japan Inc.252